Anzeige
Mehr »
Dienstag, 28.10.2025 - Börsentäglich über 12.000 News
Atomkraft feiert Comeback: Uran wird wieder zum strategischen Rohstoff - Anleger stehen Schlange
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWBU | ISIN: US21077P1084 | Ticker-Symbol: 6K9
Tradegate
28.10.25 | 12:35
1,060 Euro
-1,85 % -0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CONTEXT THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CONTEXT THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0501,09014:25
1,0501,09013:55

Aktuelle News zur CONTEXT THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrContext Therapeutics Inc. - 8-K, Current Report4
06.10.Context Therapeutics Inc.: Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting3
03.10.Context Therapeutics Inc.: Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)131PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific...
► Artikel lesen
02.09.Context Therapeutics Inc. - 8-K, Current Report1
06.08.Context Therapeutics Inc. - 10-Q, Quarterly Report3
12.06.Context Therapeutics Inc. - 8-K, Current Report2
CONTEXT THERAPEUTICS Aktie jetzt für 0€ handeln
03.06.Citizens JMP affirms $4 price target on Context Therapeutics stock4
02.06.Context Therapeutics Inc.: Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting1
02.06.Context Therapeutics Inc. - 8-K, Current Report1
29.05.Context Therapeutics names new CMO to advance T cell therapies2
29.05.Context Therapeutics Inc.: Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer301PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies...
► Artikel lesen
12.05.Context Therapeutics Inc.: Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)122PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific...
► Artikel lesen
07.05.Context Therapeutics GAAP EPS of -$0.05 beats by $0.011
07.05.Context Therapeutics Inc. - 10-Q, Quarterly Report2
05.05.Context Therapeutics ernennt neuen Interims-CMO1
05.05.Context Therapeutics Inc.: Context Therapeutics Announces Chief Medical Officer Transition318PHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies...
► Artikel lesen
09.04.Context Therapeutics Inc.: Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95203CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context's second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE)...
► Artikel lesen
20.03.Context Therapeutics Inc.: Context Therapeutics Reports Full Year 2024 Operating and Financial Results184CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027...
► Artikel lesen
24.02.Context Therapeutics Inc.: Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)169PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced...
► Artikel lesen
14.01.Context Therapeutics Inc.: Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76254CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1